1-(3,5-Dichloropyridin-2-yl)piperazine → [4-(3,5-Dichloropyridin-2-yl)piperazin-1-yl][4-(1,1-dioxo-1lambda6-isothiazolidin-2-yl)-2-methanesulfonylphenyl]methanone
반응식
[O:1]=[S:2]1(=[O:20])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[CH:15]=[CH:14][C:10]([C:11]([OH:13])=O)=[C:9]([S:16]([CH3:19])(=[O:18])=[O:17])[CH:8]=1.[Cl:21][C:22]1[C:23]([N:29]2[CH2:34][CH2:33][NH:32][CH2:31][CH2:30]2)=[N:24][CH:25]=[C:26]([Cl:28])[CH:27]=1>>[Cl:21][C:22]1[C:23]([N:29]2[CH2:34][CH2:33][N:32]([C:11]([C:10]3[CH:14]=[CH:15][C:7]([N:3]4[CH2:4][CH2:5][CH2:6][S:2]4(=[O:1])=[O:20])=[CH:8][C:9]=3[S:16]([CH3:19])(=[O:18])=[O:17])=[O:13])[CH2:31][CH2:30]2)=[N:24][CH:25]=[C:26]([Cl:28])[CH:27]=1참가 물질
3
실험 절차
Using 4-(1,1-dioxo-1λ6-isothiazolidin-2-yl)-2-methanesulfonylbenzoic acid (319 mg) described in Preparation Example 22 and 1-(3,5-dichloropyridin-2-yl)piperazine (232 mg) and by the reaction and treatment in the same manner as in Preparation Example 111, the title compound (68 mg) was obtained.